Business
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"\nTravere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in IgA nephropathy into October 2037.\n\n\nThe allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere expects to submit the issued patent for listing in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the “Orange Book”) promptly following grant.\n\n\nAbout Travere Therapeutics\nAt Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.\n\n\nFILSPARI® (sparsentan) U.S. Indication\nFILSPARI® (sparsentan) is indicated:\n\n\n\nTo slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.\n\n\n\nTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.\n\n\nIMPORTANT SAFETY INFORMATION\nBOXED WARNING: HEPATOTOXICITY AND EMBRYO-FETAL TOXICITY\nBecause of the risk of hepatotoxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Under the FILSPARI REMS, prescribers, patients and pharmacies must enroll in the program.Hepatotoxicity\nSome Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver fai...